Health Law No. 17/2023 was passed on 11 July 2023 through a plenary meeting of the House of Representatives. This law uses a lex-generalis approach to provide flexibility in transforming health services, building pharmaceutical independence, and bringing in investment in the health sector.

Business players in the pharmaceutical and medical device sectors need to anticipate the impact of the loss of lexspecialis regulations and provide input to the government to include essential matters in derivative regulations.

Vice Chairman of Kadin Indonesia for Health, Charles Honoris discussed with the Standing Committee for Pharmaceuticals and Medical Devices of Kadin Indonesia the Association of Indonesian Pharmaceutical Companies (GPFI), the International Phramaceutical Manufacturers Group (IPMG), the Association of Medical Device and Laboratory Company Organisations (GAKESLAB Indonesia), and the Indonesian Medical Device Manufacturers Association (ASPAKI) in a Focus Group Discussion held on Friday (29/9/2023).

As is known, the Ministry of Health is drafting and forming derivative regulations from the Health Law. This is a concern for business actors so that its formation fulfils the benefits for the pharmaceutical and medical device business world in Indonesia.

Kadin Indonesia will collect all input and analyses into a white paper from the business world for the Government.

The full discussion information can be found in the following attachment.